Loading
Tests whether the anthracycline can be dropped from TNBC pre-surgery treatment without losing effect.
SCARLET, SWOG trial S2212, NCT05929768, sponsored by SWOG and the NCI, tests whether the anthracycline can be dropped from pre-surgery treatment of stage II to III triple-negative breast cancer without losing effect, comparing an anthracycline-free regimen of carboplatin, docetaxel and pembrolizumab with the KEYNOTE-522 regimen. It is a non-inferiority trial of 2,400 patients with event-free survival as the primary endpoint, and success would reduce cardiotoxicity and leukaemia risk; it is ongoing with no results. OnCo links it to triple-negative breast cancer, pembrolizumab, carboplatin, the TNBC roadmap, the idea of neoadjuvant ADC plus immunotherapy replacing anthracyclines, the SWOG Cancer Research Network and Priyanka Sharma. Whether de-escalation informed by tumour-infiltrating lymphocytes and pembrolizumab can safely retire anthracyclines is the question it will answer.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease, TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line, KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC, Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease, KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares SWOG Cancer Research Network, KEYNOTE-522, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites).
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Carboplatin, Pembrolizumab.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Carboplatin, Pembrolizumab.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Carboplatin, Pembrolizumab.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Carboplatin, Pembrolizumab.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Carboplatin, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/